Long-Term Follow-Up of the Intergroup Exemestane Study.

about

Long-Term Follow-Up of the Intergroup Exemestane Study.

Item

http://www.wikidata.org/entity/Q38806937

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Long-Term Follow-Up of the Intergroup Exemestane Study.

@en

type

Item

label

Long-Term Follow-Up of the Intergroup Exemestane Study.

@en

prefLabel

Long-Term Follow-Up of the Intergroup Exemestane Study.

@en

P1154

2-s2.0-85026911800

http://www.w3.org/2001/XMLSchema#string

P1433

Journal of Clinical Oncology

P1476

Long-Term Follow-Up of the Intergroup Exemestane Study.

@en

P2093

Alan S Coates

http://www.w3.org/2001/XMLSchema#string

Claire Snowdon

http://www.w3.org/2001/XMLSchema#string

David Dodwell

http://www.w3.org/2001/XMLSchema#string

Gianfilippo Bertelli

http://www.w3.org/2001/XMLSchema#string

Hanna Nicholas

http://www.w3.org/2001/XMLSchema#string

Judith M Bliss

http://www.w3.org/2001/XMLSchema#string

Jørn Andersen

http://www.w3.org/2001/XMLSchema#string

Lesley Fallowfield

http://www.w3.org/2001/XMLSchema#string

Lucia Del Mastro

http://www.w3.org/2001/XMLSchema#string

Lucy Kilburn

http://www.w3.org/2001/XMLSchema#string

P2860

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

Factors predicting late recurrence for estrogen receptor-positive breast cancer

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.

P304

2507-2514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.70.5640

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Per Eystein Lønning

Jacek Jassem

Cornelis van de Velde

James P Morden

Isabel Alvarez

P5530

19844575

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085131029

http://www.w3.org/2001/XMLSchema#string

P698

28467729

http://www.w3.org/2001/XMLSchema#string

P932

6175047

http://www.w3.org/2001/XMLSchema#string

P953

120555/